Format

Send to

Choose Destination
World J Gastroenterol. 2016 May 7;22(17):4275-86. doi: 10.3748/wjg.v22.i17.4275.

Dendritic cell-based cancer immunotherapy for colorectal cancer.

Author information

1
Mikio Kajihara, Kazuki Takakura, Tomoya Kanai, Zensho Ito, Keisuke Saito, Shinichiro Takami, Toshifumi Ohkusa, Shigeo Koido, Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine (Kashiwa Hospital), Kashiwa, Chiba 277-8567, Japan.

Abstract

Colorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer-related mortality worldwide. Although systemic therapy is the standard care for patients with recurrent or metastatic CRC, the prognosis is extremely poor. The optimal sequence of therapy remains unknown. Therefore, alternative strategies, such as immunotherapy, are needed for patients with advanced CRC. This review summarizes evidence from dendritic cell-based cancer immunotherapy strategies that are currently in clinical trials. In addition, we discuss the possibility of antitumor immune responses through immunoinhibitory PD-1/PD-L1 pathway blockade in CRC patients.

KEYWORDS:

Cancer immunotherapy; Colorectal cancer; Cytotoxic T lymphocyte; Dendritic cell; Immune-checkpoint inhibitors

PMID:
27158196
PMCID:
PMC4853685
DOI:
10.3748/wjg.v22.i17.4275
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center